ATHENEX INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
ATHENEX INC. - More news...
ATHENEX INC. - More news...
- Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update
- Athenex Announces Participation at the Cowen 40th Annual Health Care Conference
- Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020
- Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma
- Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao
- Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer
- Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019
- Athenex Announces $60 Million Private Placement
- Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium
- Athenex, Inc. Announces Third Quarter 2019 Financial Results
- Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma
- Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment
- Athenex Provides An Update to Shareholders
- Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019
- Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
- Athenex Completes Construction of New API Facility in Chongqing
- Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
- Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical
- Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy
- Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
- Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
- Athenex Provides an Update Regarding the Vasopressin Case
- Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019
- Athenex Announces Strategic Global Initiatives to Expand Clinical Operations
- Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
- Athenex Provides an Update on its Chongqing API Plant
- Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
- Athenex to Present at the 2019 ASCO Annual Meeting
- Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update
- Athenex Announces $100 Million Private Placement
